9Q486_HemaSphereBooklet_V5_53019_FLIPBOOK-compressed

LETTER FROM THE EDITORS

HemaSphere was launched in 2017 as the official journal of the European Hematology Association (EHA). HemaSphere is not just another online journal in the field of hematology, but aims to support hematology researchers by offering a fast and constructive review process, full open access and low publication fees. The journal publishes basic, translational and clinical research of very high level as well as insightful review articles with recommendations for future research and clinical applications. A series of review articles on CAR-T cell therapy was published in 2019. HemaSphere is also a hematology information resource, with discussions and opinions on recent evolutions published in the HemaTopics section of the journal. PubMed Central ® is reviewing the journal’s application for indexing and a decision is expected soon.

Andreas Engert, MD Prof. Dr. Andreas Engert is a specialist in Internal Medicine, Hematology and Oncology at the University Hospital in Cologne, Germany. He is the chairman of the German Hodgkin Study Group (GHSG). Based on a number of experimental research model, the treatment of Hodgkin lymphoma has substantially improved with nearly 20.000 Hodgkin lymphoma patients treated within GHSG clinical

trials. More recently, targeted drugs such as checkpoint inhibitors opened new perspectives for Hodgkin lymphoma that will lead to further reduction of chemo- and radiotherapy in this disease.

Jan Cools, PhD Jan Cools is Professor at the Center for Cancer Biology of VIB and KU Leuven (Leuven, Belgium). His research focuses on the genetics of acute lymphoblastic leukemia and on the development of mouse models to study the role of oncogenes.